None listed
Conditions
Interventions
None listed
Sponsors
Keimyung University Dongsan Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who are scheduled to receive SARS-CoV-2 vaccine (BNT162b2, mRNA-1273) among IBD patients aged 20 to 80 years 2. Patients who are expected to complete SARS-CoV-2 vaccination among IBD patients aged 20 to 80 years 3. A person who has signed a written consent form after agreeing to the purpose and method of the clinical research 4. Patients taking 5-aminosalicylic acid (ASA), immunomodulatory agents, or biological agents (infliximab or vedolizumab) among Crohn's disease/ulcerative colitis patients
Exclusion criteria
Exclusion criteria: 1. Patients with IBD for whom information on adverse reactions related to vaccination cannot be obtained 2. Patients with acute illness who have been hospitalized within 4 weeks of starting vaccination 3. Patients who have had surgery within 3 months 4. Those who have passed more than 19 weeks after completing the second dose of vaccine 5. Subjects who do not agree to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Antibody to SARS-CoV-2 | — |
Secondary
| Measure | Time frame |
|---|---|
| vacine-related adverse reactions | — |
Countries
Korea, Republic of
Contacts
Public ContactJeongseok Kim
Keimyung University Dongsan Hospital
Outcome results
None listed